• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC

Opinion
Video

Neal Shore, MD, FACS, discuss the key efficacy outcomes reported for nadofaragene firadenovec (ADSTILADRIN) in the phase 3 trial for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) and compare these long-term results to other bladder-preserving therapies in this population.

Related Videos
4 experts in this video
4 experts in this video
Screenshot of a webinar panel discussion with Viet Le, PA-C; Nathan Wong, PhD, MPH; Alison Bailey, MD; and Martha Gulati, MD, MS
World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com
2 experts in this video
2 experts in this video
Dr Sundar Jagannath
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.